ପିମାଭାନସେରିନ

ପିମାଭାନସେରିନ
Clinical data
Trade names	Nuplazid
Synonyms	ACP-103; BVF-048
AHFS/Drugs.com	monograph
Routes of; administration	By mouth (tablets)
Legal status
Legal status	US: ℞-only ;
Pharmacokinetic data
Protein binding	94–97%
Metabolism	Liver (CYP3A4, CYP3A5, CYP2J2)
Elimination half-life	54–56 hours
Identifiers
	IUPAC name N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide;
Chemical and physical data
Formula	C25H34FN3O2
Molar mass	୪୨୭.୫୬ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)COc3ccc(cc3)CNC(=O)N(C(CC2)CCN2C)Cc(cc1)ccc1F;
	InChI InChI=1S/C25H34FN3O2/c1-19(2)18-31-24-10-6-20(7-11-24)16-27-25(30)29(23-12-14-28(3)15-13-23)17-21-4-8-22(26)9-5-21/h4-11,19,23H,12-18H2,1-3H3,(H,27,30) ; Key:RKEWSXXUOLRFBX-UHFFFAOYSA-N ;
(verify)

ଇଂରାଜୀ ଲିଙ୍କ

https://or.wikipedia.org/wiki/Pimavanserin

ପିମାଭାନସେରିନ, ଏକ ବେପାର ନାମ ନ୍ୟୁପ୍ଲାଜିଡ, ହେଉଛି ଏକ ଔଷଧ ଯାହା ପାର୍କିନ୍‌ସନ୍ ରୋଗରେ ହେଉଥିବା ସାଇକୋସିସର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।^[୩] ଡିମେନ୍ସିଆ କାରଣରୁ ହେଉଥିବା ସାଇକୋସିସ୍ ପାଇଁ ଏହା ସୁପାରିଶ କରାଯାଏ ନାହିଁ ।^[୩] ଏହା ପାଟିଦ୍ୱାରା ନିଆଯାଏ ।^[୩]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଫୁଲା ଏବଂ ଦ୍ୱନ୍ଦ୍ୱ ହୋଇପାରେ ।^[୪] ଅନ୍ୟାନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ କ୍ୟୁଟି (QT) ବିସ୍ତାର ହୋଇପାରେ ।^[୪] ଯକୃତ ଜନିତ ସମସ୍ୟାରେ ସୁପାରିଶ କରାଯାଏ ନାହିଁ ।^[୩] ଏହା ଏକ ଆଟିପିକାଲ୍ ଆଣ୍ଟିସାଇକୋଟିକ | ^[୩] ଏହା କିପରି କାର୍ଯ୍ୟ କରେ ତାହା ସ୍ପଷ୍ଟ ନୁହେଁ କିନ୍ତୁ ସେରୋଟୋନିନ୍ ରିସେପ୍ଟର ଉପରେ ପ୍ରଭାବ ପକାଇପାରେ ।^[୩]

୨୦୧୬ ମସିହାରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଡାକ୍ତରୀ ବ୍ୟବହାର ପାଇଁ ପିମାଭାନସେରିନ ଅନୁମୋଦିତ ହୋଇଥିଲେ ।^[୩] ୟୁରୋପ କିମ୍ବା ବ୍ରିଟେନରେ ଏହା ଅନୁମୋଦିତ ନୁହେଁ।^[୫] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ୨୦୨୧ ସୁଦ୍ଧା ଏହା ପିଛା ମାସକୁ ପ୍ରାୟ ୪,୨୦୦ ଡଲାର ଖର୍ଚ୍ଚ ହୋଇଥାଏ ।^[୬]

ଆଧାର

1 2 Friedman JH (October 2013). "Pimavanserin for the treatment of Parkinson's disease psychosis". Expert Opinion on Pharmacotherapy. 14 (14): 1969–75. doi:10.1517/14656566.2013.819345. PMID 24016069. S2CID 35649566.
↑ "Nuplazid (pimavanserin) Tablets, for Oral Use. U.S. Full Prescribing Information" (PDF). ACADIA Pharmaceuticals Inc. Archived from the original (PDF) on 3 October 2018. Retrieved 5 Nov 2018.
1 2 3 4 5 6 7 "Pimavanserin Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 25 January 2021. Retrieved 28 October 2021.
1 2 "DailyMed - NUPLAZID- pimavanserin tartrate capsule NUPLAZID- pimavanserin tartrate tablet, coated". dailymed.nlm.nih.gov. Archived from the original on 4 May 2021. Retrieved 28 October 2021.
↑ "Pimavanserin". SPS - Specialist Pharmacy Service. 1 January 2016. Archived from the original on 28 October 2021. Retrieved 28 October 2021.
↑ "Nuplazid Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 16 January 2021. Retrieved 28 October 2021.

[Rev-1] 1 2 Friedman JH (October 2013). "Pimavanserin for the treatment of Parkinson's disease psychosis". Expert Opinion on Pharmacotherapy. 14 (14): 1969–75. doi:10.1517/14656566.2013.819345. PMID 24016069. S2CID 35649566.

[PI-2] "Nuplazid (pimavanserin) Tablets, for Oral Use. U.S. Full Prescribing Information" (PDF). ACADIA Pharmaceuticals Inc. Archived from the original (PDF) on 3 October 2018. Retrieved 5 Nov 2018.

[AHFS2021-3] 1 2 3 4 5 6 7 "Pimavanserin Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 25 January 2021. Retrieved 28 October 2021.

[PI2021-4] 1 2 "DailyMed - NUPLAZID- pimavanserin tartrate capsule NUPLAZID- pimavanserin tartrate tablet, coated". dailymed.nlm.nih.gov. Archived from the original on 4 May 2021. Retrieved 28 October 2021.

[SP2021-5] "Pimavanserin". SPS - Specialist Pharmacy Service. 1 January 2016. Archived from the original on 28 October 2021. Retrieved 28 October 2021.

[6] "Nuplazid Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 16 January 2021. Retrieved 28 October 2021.

[୧]

[୨]

[୩]

[୪]

[୫]

[୬]